Abstract
Introduction: In 2013, the Center for Disease Control (CDC) designated methicillin-resistant Staphylococcus aureus (MRSA) as a serious threat. In addition to its intrinsic virulence, MRSA has become resistant to numerous antibacterial agents. In many instances, mupirocin is used empirically to decolonize patients harboring MRSA to decrease the possibility of progression to disease. In vitro susceptibility information is critical to identify patients who would benefit from use of mupirocin for decolonization and treatment of infections caused by MRSA. Methods: One-hundred and sixty-three recent MRSA single patient clinical isolates were collected from the Clinical Microbiology Laboratory. In-vitro susceptibility testing was performed using E-test methodology for tigecycline, ceftaroline, daptomycin, vancomycin, linezolid, and mupirocin. Results: Of the 163 MRSA isolates tested, >99% demonstrated susceptibility to tigecycline, ceftaroline, daptomycin, vancomycin, and linezolid. Seventy (43%) had vancomycin MICs ≥ 1.5 μg/ml, twenty-four isolates (15%) were resistant to mupirocin, and three appeared to express mupirocin hetero-resistance. Conclusion: While antibiotic susceptibility to mupirocin is not routinely performed in clinical microbiology laboratories, the level of resistance to mupirocin identified in this surveillance study suggests that susceptibility testing should be added to routine MRSA panels.
Highlights
In 2013, the Center for Disease Control (CDC) designated methicillin-resistant Staphylococcus aureus (MRSA) as a serious threat
A recent survey from the CDC on antimicrobialresistant pathogens associated with healthcare-associated infections (HAIs) found MRSA to be associated with 54.6% of central line-associated bloodstream infections (CLABSI), 58.7% of catheter-associated urinary tract infections (CAUTI), 48.4% of ventilator-associated pneumonia (VAP), and 43.7% of surgical site infections (SSI) [4]
The total annual costs for CLABSI, VAP, SSI, Clostridium difficile associated infection and CAUTI was estimated at 9.8 billion US dollars [7]
Summary
In 2013, the Center for Disease Control (CDC) designated methicillin-resistant Staphylococcus aureus (MRSA) as a serious threat. Methicillin-resistant Staphylococcus aureus (MRSA) is a ubiquitous, virulent pathogen found in a variety of hospital, long-term care facility and community settings [1] [2]. It has been recognized as a serious threat by the Center for Disease Control and Prevention (CDC) in 2013 [3]. As mupirocin susceptibility is not routinely performed in most clinical microbiology laboratories, it is assumed to be an active agent when used This in vitro susceptibility surveillance study using E-test methodology was undertaken to determine mupirocin susceptibility along with comparator antibiotics against recent MRSA isolated from a variety of clinical patient specimens
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
